QRL-101
ALS (Hyperexcitability), Epilepsy, Pain
Phase 1Active
Key Facts
About QurAlis
QurAlis is a private, clinical-stage biotech pioneering precision therapies for neurodegenerative diseases, primarily ALS and FTD. The company leverages its proprietary FlexASO® antisense oligonucleotide platform and deep understanding of TDP-43 pathology to develop targeted treatments. Its pipeline includes two lead clinical-stage assets: QRL-201, a first-in-class therapy targeting STATHMIN-2 restoration for sporadic ALS, and QRL-101, a selective Kv7.2/7.3 ion channel opener for ALS hyperexcitability, epilepsy, and pain. The company is advancing a biomarker-defined, precision medicine strategy in a high-need therapeutic area.
View full company profile